SOUTH SAN FRANCISCO, Calif., June 04, 2021 (GLOBE NEWSWIRE)Cellworks Group, Inc., a world leader in Personalized Medicine in the key therapeutic areas of Oncology and Immunology, today announced results from the myCare-022-05 prospectively designed study on a retrospective TCGA cohort, which demonstrate that the Cellworks Singula Therapy Response Index (TRI) is strongly predictive of Overall Survival (OS), Progression-Free Survival (PFS) and clinical benefit for non-small cell lung cancer (NSCLC) patients. In this study, Singula TRI provided predictive value to physicians beyond standard clinical factors, including patient age, patient gender and physician-prescribed treatment.